Cellevate strengthens its Scientific Advisory Board by appointing Dr. Yvonne Genzel, a vaccine production leading expert


LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that PD Dr. Yvonne Genzel, has been appointed to the company’s Scientific Advisory Board. Dr. Genzel is since 2001 member of the Bioprocess Engineering group at the Max-Planck-Institute for Dynamics of Complex Technical Systems, in Magdeburg, Germany, responsible for the Upstream Processing Team focusing on virus production with mammalian cells. In 2009 Dr. Genzel received her habilitation (PD) in “Upstream processing issues in influenza vaccine production using animal cell technology” at the Otto-von-Guericke-University, Magdeburg. Dr. Genzel has more than 90 peer-reviewed papers on vaccine production using cell culture-based processes.

“Many virus producing cells perform better with increased cell growth surface. I am always curious to evaluate new developments for cell culture. Therefore, I am very happy to be able to support Cellevate as a member of the Scientific Advisory Board”, says Dr. Yvonne Genzel.

“We are delighted that Dr. Yvonne Genzel has agreed to join our Scientific Advisory Board. She is a globally recognized expert in the field of vaccines bioprocess engineering, especially animal cell culture and virus production in bioreactor systems. Dr. Genzel’s broad knowledge and experience in the vaccines field will perfectly complement the other Scientific Advisory Board members expertise and will support us with the design of the validation program as well as overall strategic expertise for the market introduction of the Cellevat3d™ microcarriers in 2024″, says Laura Chirica, CEO Cellevate.  

More information about Cellevate’s Scientific Advisory Board members.

For more information, please contact:

Laura Chirica, PhD

CEO Cellevate

Email: laura.chirica@cellevate.com

About Cellevate

Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center. The company founded in 2014, develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of microcarriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ microcarriers products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ microcarriers have a commercial launch and sales start planned for 2024.

For more information, please visit www.cellevate.com.